Progression-free survival as endpoint in metastatic RCC?
Knox
Jennifer J
JJ
Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada. jennifer.knox@uhn.on.ca
D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015415:Biomarkers; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D017326:Clinical Trials, Phase III as Topic; D018592:Cross-Over Studies; D018572:Disease-Free Survival; D000068338:Everolimus; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000556:secondary; D011237:Predictive Value of Tests; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic / Q000941:ethics*; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016019:Survival Analysis
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D015415:Biomarkers; D007166:Immunosuppressive Agents; D000068338:Everolimus; D020123:Sirolimus